Unilever to acquire Horlicks in US$3.8bn GSK Health Food Drinks portfolio deal
03 Dec 2018 --- Unilever has emerged as the winner in the bid to acquire hot drink brand Horlicks, by signing an agreement to acquire the Health Food Drinks portfolio (GSK HFD) of GlaxoSmithKline (GSK) in India, Bangladesh and 20 other predominantly Asian markets. Unilever’s share of the total consideration is US$3.8 billion (€3.3 billion) and the company notes that the transaction is aligned with its strategy which seeks to increase its presence in health-food categories and high-growth emerging markets. The transaction consists of three elements:
Last year, the GSK HFD portfolio delivered a total turnover of US$623 million (€550 million), primarily through the Horlicks and Boost brands, with almost 90 percent of the turnover being in India. Horlicks products have been an everyday staple in South Asian households for generations. Over the last 15 years, the portfolio and category have grown at a double-digit rate. Despite this, the category still remains under-penetrated in India, the company notes. However, Unilever is well positioned to further develop the market given the extent of its reach and capabilities. “The acquisition is transformative for our Foods and Refreshment business, allowing us to enter the Health Foods Drinks category, further strengthening our position in health and wellness. It is rare to be able to acquire brands with such leading market positions and fantastic consumer equity in one of the world’s most exciting and fast-growing markets. Improving the health and wellbeing of 1 billion people by 2020 is a key pillar in our Unilever Sustainable Living Plan. Horlicks and Boost will add to our stable of purpose-driven brands that help consumers to get more out of their lives,” says Nitin Paranjpe, President, Food & Refreshment, Unilever. The race is over As part of a major UK review last July, GSK announced it was making strategic decisions concerning its consumer healthcare business and pharmaceuticals, including options to divest some nutrition brands and its intention to sell its Horlicks brand in the UK. By March this year, GSK reached an agreement with Novartis for the buyout of Novartis’ 36.5 percent stake in their Consumer Healthcare Joint Venture for US$13 billion. Long-established Horlicks, which is sold through GSK’s Indian subsidiary, has a solid track record. Speaking during a press conference call held earlier this year, GSK CEO Emma Walmsley, stressed that India remains a priority market for GSK, a key location for growth opportunities. Walmsley also described Horlicks as “absolutely extraordinary brand with more than a century of history in India.” To contact our editorial team please email us at editorial@cnsmedia.com
Related ArticlesHealth & Nutrition News Asda on track with vegan product certification as trend intensifies19 Feb 2019 --- Major UK retailer Asda is on track for a significant vegan reformulation and labeling drive. Two years after revealing a partnership with The Vegan Society, the certification body says that they are well on the way to having a wide range of products certified. “They are making great strides in getting everything that is vegan registered with us,” Chantelle Adkins, Head of Business Development for The Vegan Society, tells NutritionInsight at last week’s organic foods trade fair, Biofach 2019, in Germany. Health & Nutrition News Late night cravings? Nightfood ice cream provides some sleep-friendly indulgence18 Feb 2019 --- Tapping into the growing snacking trend, Nightfood Inc. has launched a line of ice creams that boast a low-calorie, sleep-friendly formulation. Although the products do not contain any sleep activating chemicals such as melatonin, they are touted as not interfering with sleep due to their reduced sugar, caffeine and fat content. The company has announced its first major retail distribution deal which launches nationwide in the US this month. Health & Nutrition News Examining DNA derived from GM foods: Scientists probe how it penetrates the body's cells22 Jan 2019 --- Toxicologists, including scientists from the Far Eastern Federal University (FEFU), studying the potential risks of genetically modified (GM) products have published a review on the fate of the DNA derived from GM food and how it can survive during digestion and penetrate into the cells of the body. One of the key findings is that the micro-ribonucleic acid – one of the main molecules in cells of living organisms – of GM foods that were treated with insecticides and antiviral sprays can affect genetic processes in the bodies of those who consume it. Health & Nutrition News Lipid-based supplement found to benefit psychomotor development in children18 Jan 2019 --- A recent study has found that a new lipid-based nutrient supplement may positively impact the development of older infants. The study, published in The American Journal of Clinical Nutrition, is the joint effort of DSM, the North West University of South Africa, the Global Alliance for Improved Nutrition (GAIN) and Unilever. The findings revealed that children who consumed the supplement showed enhanced growth and psychomotor development, as well as high iron levels. Business News “Landmark day”: GSK and Pfizer to form new Consumer Healthcare Joint Venture19 Dec 2018 --- Pharma heavyweights GlaxoSmithKline plc (GSK) and Pfizer Inc. have reached an agreement to combine the two companies’ consumer health businesses into a “new world-leading” Joint Venture, with combined sales of approximately £9.8 billion (US$12.7 billion). As a result of this JV, GSK intends to split into two businesses in the next three years – for prescription drugs and vaccines and for OTC products, including vitamin and mineral supplements. GSK is to hold a majority controlling equity interest of 68 percent, while Pfizer will have an equity interest of 32 percent in the Joint Venture. More Articles |
